Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$307.99 +1.1%	$270.09	$152.30 ▼ $310.22	$40.16B	0.22	929,813 shs	571,872 shs
BGNE BeiGene		$194.32	$141.31 ▼ $248.16	$18.03B	0.57	323,752 shs	331,608 shs
GMAB Genmab A/S	$22.82 -1.2%	$20.56	$17.24 ▼ $28.56	$14.63B	0.96	1.17 million shs	1.11 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+2.38%	+7.95%	+21.68%	+92.03%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+13.61%
GMAB Genmab A/S	0.00%	+2.79%	+14.79%	+9.71%	-12.87%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2416 of 5 stars	2.4	5.0	0.0	4.3	3.4	2.5	0.6
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	3.8268 of 5 stars	3.3	5.0	0.0	0.0	2.4	0.0	3.1
HZNP Horizon Therapeutics Public	1.1363 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.76% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	71.63% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGNE, GMAB, ALNY, and HZNP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
5/2/2025	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $349.00
5/2/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $325.00
4/11/2025	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$284.00 ➝ $268.00
4/9/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/31/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$338.00 ➝ $342.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$353.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $345.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.35B	17.10	N/A	N/A	$0.52 per share	592.29
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
GMAB Genmab A/S	$3.12B	4.70	$1.54 per share	14.80	$8.04 per share	2.84
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	346.06	N/A	-12.37%	N/A	-6.83%	7/30/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
GMAB Genmab A/S	$1.14B	$1.76	13.11	12.82	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A

Latest BGNE, GMAB, ALNY, and HZNP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BGNE BeiGene	0.05	1.93	1.72
GMAB Genmab A/S	N/A	5.25	5.24
HZNP Horizon Therapeutics Public	0.48	4.27	4.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BGNE BeiGene	48.55%
GMAB Genmab A/S	7.07%
HZNP Horizon Therapeutics Public	80.37%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BGNE BeiGene	7.43%
GMAB Genmab A/S	1.54%
HZNP Horizon Therapeutics Public	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,000	130.39 million	127.52 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
GMAB Genmab A/S	1,660	641.22 million	651.58 million	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable

BGNE, GMAB, ALNY, and HZNP Headlines

Recent News About These Companies

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

February 8, 2025 | markets.businessinsider.com

Horizon Therapeutics Public Lim (HZNP)

April 27, 2024 | finance.yahoo.com

PAC Profile: Horizon Therapeutics

December 25, 2023 | opensecrets.org

5 Biotech Acquisition Targets To Accumulate In 2024

December 21, 2023 | seekingalpha.com

Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business Combination

November 16, 2023 | msn.com

Horizon Therapeutics cut jobs in Deerfield after Amgen acquisition

October 24, 2023 | chicago.suntimes.com

350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by Amgen

October 24, 2023 | msn.com

Rule 17(e) Announcement - Horizon Therapeutics plc

October 6, 2023 | finance.yahoo.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

October 5, 2023 | stocknews.com

Rule 17(d) Announcement - Horizon Therapeutics plc

October 5, 2023 | stockhouse.com

Rule 17(d) Announcement – Horizon Therapeutics plc

October 5, 2023 | finance.yahoo.com

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

October 2, 2023 | finance.yahoo.com

Horizon Therapeutics Plc (HZNP) Becoming More Attractive for Investors

September 27, 2023 | knoxdaily.com

Board Member at Horizon Therapeutics Exercises Options Worth $2.31M

September 26, 2023 | benzinga.com

Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry

September 26, 2023 | finance.yahoo.com

Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List

September 19, 2023 | finance.yahoo.com

Health care: FTC Chair Lina Khan to crack down on 'below radar' deals

September 19, 2023 | finance.yahoo.com

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

September 13, 2023 | finance.yahoo.com

HZNP short interest jump by 15.39%, reflecting negative sentiment

September 7, 2023 | knoxdaily.com

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

September 5, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGNE, GMAB, ALNY, and HZNP Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$307.99 +3.32 (+1.09%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$307.83 -0.16 (-0.05%)

As of 07:00 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Genmab A/S NASDAQ:GMAB

$22.82 -0.27 (-1.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$22.99 +0.17 (+0.73%)

As of 07:03 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time